Oh, and have a good Christmas all. Look forward to a rapid run to positive cash flows in 2024, that OCC would already be enjoying were it not for it's R&D expenditure, which is of course mainly getting Remplir and ATI to market in the US. An investment of capital and cash flows that none of us would disagree with.
l
Ann: Orthocell Board Change, page-4
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $75.35M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 36.0¢ | 35.5¢ | $51.60K | 145.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 145099 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 131882 | 2 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| OCC (ASX) Chart |